Tina AlbertsonCMO and Head of Development at Lyell Immunopharma, USA
Tina Albertson, M.D., Ph.D., has spent her career advancing innovative oncology therapies. She has served as Lyell’s Chief Medical Officer and Head of Development since July 2020. Prior to joining Lyell, Dr. Albertson was Vice President of Global Drug Development responsible for the development and registration strategy for Breyanzi® (lisocabtagene maraleucel), at Juno Therapeutics, a BMS company. Dr. Albertson is a pediatric oncologist who trained at Seattle Children’s Hospital and the FHCRC. Dr. Albertson earned a Ph.D. in Cancer Biology from University of Washington, an M.D. from Stanford University, and a B.S. in Molecular Biology from University of Oregon.